Inclusion criteria :
Patient with Rheumatoid Arthritis (RA) who was previously randomized in the sarilumab RA clinical program: e.g., the EFC11072 study, ACT11575 study, EFC10832 study, or SFY13370 study.
Exclusion criteria:
Patient with any adverse event leading to permanent study drug discontinuation from a prior study.
Treatment with any concurrent biologic agents including investigational drugs for the treatment of Rheumatoid Arthritis (RA).
Patients with an abnormality(ies) or adverse event(s) that per investigator judgment would adversely affect participation of the patient in the study.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01146652?cond=%22Arthritis%22&lup_s=10/31/2013&lup_d=30
